CoV-2–specific T-cell response (defined as IFN-ɣ concentration ≥0.15 IU/mL after specific stimulation) was observed in 87.5% and 75.0% of controls, 77.8% and 69.4% of CKD G4/5 patients, and 73.3% and 52.6% of dialysis patients at 28 days and 6 months, respectively (P < .001, P = .002, and P < .001, respectively; Figure 5A). The gene discussed is IFNA1; the disease is chronic kidney disease.